Kallisio recently announced that the FDA has cleared its 3D-printed Stentra, used to protect head and neck cancer patient’s healthy tissue during radiation therapy.
Thirona announced today that it received FDA 510(k) clearance for the latest update of its AI-based LunQ clinical software.
Pi-Cardia announced today that the FDA granted breakthrough device designation for its ShortCut leaflet modification device.
Short, toxic RNAs kill brain cells and may allow Alzheimer’s to develop
Quibim, a company using imaging biomarkers for precision medicine, has added a new cancer detection capability to its prostate tool based on AI, QP-Prostate. The updated product, which uses algorithms trained on actual pathology data as ground truth, has been given a CE mark for the European Union and a UKCA mark for the United Kingdom.
The advance makes it easier to detect circulating tumor DNA in blood samples, which could enable earlier cancer diagnosis and help guide treatment.
MIT CSAIL researchers develop advanced machine-learning models that outperform current methods in detecting pancreatic ductal adenocarcinoma.
Abbott (NYSE: ABT)+
announced today that the FDA approved expanded MRI labeling for its Proclaim DRG neurostimulation system.
The de novo classifications cover software for detecting a lung condition and assessing dementia risk.
NeuroSigma today announced that the U.S. Food and Drug Administration (FDA) cleared use of NeuroSigma’s second-generation Monarch eTNS System for treating pediatric attention deficit hyperactivity disorder (ADHD)